


SURG 5100

Biopharmaceutical Drug Development

FALL 2026
3 CREDITS
CRN 96270

Of a hundred programs that start,
two reach a patient.

This course is about the ninety-eight — where they stopped, what it cost, and which decision would have caught it a year earlier.



OF 100 PROGRAMS ENTERING DISCOVERY — SQUARE-ROOT SCALE, ILLUSTRATIVE BENCHMARKS
Reaching the market is not the end: some approved drugs are later restricted or withdrawn.

TAUGHT WITH INDUSTRY

Matt Whelihan, PhD
Research & Development · Prolytix Technologies

A working industry scientist in the room every week — not a guest lecture.

with Dev Majumdar, PhD · Larner College of Medicine & Biomedical Engineering

- 01 **Site visits** to Vermont pharmaceutical and biotechnology operations.
- 02 **Founders and CEOs** as guests, with quality and regulatory leads who file with the FDA.
- 03 **Undergraduates and graduate students** in the same room.

✓ ELECTIVE CREDIT, MOST DEPARTMENTS ✓ ALL LEVELS ask your advisor how it applies to your program



Tuesday & Thursday, 11:40 a.m. – 12:55 p.m.
University of Vermont · uvm5100.pages.dev

SYLLABUS &
FULL SCHEDULE